117 related articles for article (PubMed ID: 9304878)
1. Expression and immunogenicity of V3 loop epitopes of HIV-1, isolates SC and WMJ2, inserted in Salmonella flagellin.
Cattozzo EM; Stocker BA; Radaelli A; De Giuli Morghen C; Tognon M
J Biotechnol; 1997 Aug; 56(3):191-203. PubMed ID: 9304878
[TBL] [Abstract][Full Text] [Related]
2. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
3. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
4. Expression and immunogenicity of an 18-residue epitope of HIV1 gp41 inserted in the flagellar protein of a Salmonella live vaccine.
Newton SM; Joys TM; Anderson SA; Kennedy RC; Hovi ME; Stocker BA
Res Microbiol; 1995; 146(3):203-16. PubMed ID: 7569315
[TBL] [Abstract][Full Text] [Related]
5. Multiepitope polypeptide of the HIV-1 envelope induces neutralizing monoclonal antibodies against V3 loop.
Duarte CA; Montero M; Seralena A; Valdés R; Jiménez V; Benítez J; Narciandi E; Madrazo J; Padrón G; Sánchez G
AIDS Res Hum Retroviruses; 1994 Mar; 10(3):235-43. PubMed ID: 7517147
[TBL] [Abstract][Full Text] [Related]
6. Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains.
Kayman SC; Wu Z; Revesz K; Chen H; Kopelman R; Pinter A
J Virol; 1994 Jan; 68(1):400-10. PubMed ID: 7504740
[TBL] [Abstract][Full Text] [Related]
7. Impact of epitope permutations in the antibody response of mice to a multi-epitope polypeptide of the V3 loop of human immunodeficiency virus type 1.
Aguilar A; Carrazana Y; Duarte CA
Biomol Eng; 2001 Oct; 18(3):117-24. PubMed ID: 11566603
[TBL] [Abstract][Full Text] [Related]
8. Expression and immunogenicity of a streptococcal M protein epitope inserted in Salmonella flagellin.
Newton SM; Kotb M; Poirier TP; Stocker BA; Beachey EH
Infect Immun; 1991 Jun; 59(6):2158-65. PubMed ID: 2037377
[TBL] [Abstract][Full Text] [Related]
9. Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine.
Rovinski B; Haynes JR; Cao SX; James O; Sia C; Zolla-Pazner S; Matthews TJ; Klein MH
J Virol; 1992 Jul; 66(7):4003-12. PubMed ID: 1602531
[TBL] [Abstract][Full Text] [Related]
10. Antigenicity and immunogenicity of the V3 domain of HIV type 1 glycoprotein 120 expressed on the surface of Streptococcus gordonii.
Oggioni MR; Medaglini D; Romano L; Peruzzi F; Maggi T; Lozzi L; Bracci L; Zazzi M; Manca F; Valensin PE; Pozzi G
AIDS Res Hum Retroviruses; 1999 Mar; 15(5):451-9. PubMed ID: 10195755
[TBL] [Abstract][Full Text] [Related]
11. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
[TBL] [Abstract][Full Text] [Related]
12. Improved humoral and cellular immune responses against the gp120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted into the hepatitis B surface antigen.
Fomsgaard A; Nielsen HV; Bryder K; Nielsen C; Machuca R; Bruun L; Hansen J; Buus S
Scand J Immunol; 1998 Apr; 47(4):289-95. PubMed ID: 9600309
[TBL] [Abstract][Full Text] [Related]
13. A single point mutation in HIV-1 V3 loop alters the immunogenic properties of rgp120.
Lee SK; Pestano GA; Riley J; Hasan AS; Pezzano M; Samms M; Park KJ; Guyden J; Boto WM
Arch Virol; 2000; 145(10):2087-103. PubMed ID: 11087093
[TBL] [Abstract][Full Text] [Related]
14. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
15. Comparative studies on neutralisation of primary HIV-1 isolates by human sera and rabbit anti-V3 peptide sera.
Lawoko AL; Johansson B; Hjalmarsson S; Christensson B; Ljungberg B; Al-Khalili L; Sjölund M; Pipkorn R; Fenyö EM; Blomberg J
J Med Virol; 1999 Oct; 59(2):169-79. PubMed ID: 10459152
[TBL] [Abstract][Full Text] [Related]
16. V3 loop core region serotyping of HIV-1 infected patients using the FHV epitope presenting system.
Schiappacassi M; Buratti E; D'Agaro P; Ciani L; Scodeller ES; Tisminetzky SG; Baralle FE
J Virol Methods; 1997 Jan; 63(1-2):121-7. PubMed ID: 9015282
[TBL] [Abstract][Full Text] [Related]
17. Characterization of an internal permissive site in the cholera toxin B-subunit and insertion of epitopes from human immunodeficiency virus-1, hepatitis B virus and enterotoxigenic Escherichia coli.
Bckström M; Holmgren J; Schödel F; Lebens M
Gene; 1995 Nov; 165(2):163-71. PubMed ID: 8522171
[TBL] [Abstract][Full Text] [Related]
18. Principal neutralizing domain of HIV-1 is highly immunogenic when expressed on the surface of hepatitis B core particles.
von Brunn A; Brand M; Reichhuber C; Morys-Wortmann C; Deinhardt F; Schödel F
Vaccine; 1993; 11(8):817-24. PubMed ID: 7689283
[TBL] [Abstract][Full Text] [Related]
19. Evidence of no change in V3 loop antibody recognition pattern in HIV type 1-infected Ethiopians between 1988 and 1993.
Sherefa K; Sällberg M; Sönnerborg A
AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1551-6. PubMed ID: 7534097
[TBL] [Abstract][Full Text] [Related]
20. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
